# Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

> **NCT06017609** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akros Pharma Inc.** · enrollment: 314 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** JTT-861 Capsules
- **DRUG:** Placebo Capsules

## Key facts

- **NCT ID:** NCT06017609
- **Lead sponsor:** Akros Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06017609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06017609, "Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06017609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*